MedTrace Logo

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

NCT06459193 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-30

No results posted yet for this study

Summary

This proof-of-concept study evaluated the effect of Trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.

Conditions

  • Peripheral Neuropathy Due to Chemotherapy

Interventions

DRUG

Trimetazidine

Trimetazidine 35 mg tab once daily

DRUG

Placebo

Placebo once daily

Sponsors & Collaborators

  • Minia University

    lead OTHER

Principal Investigators

  • Asmaa N. Iqbal Ahmed, Demonstrator · Clinical Pharmacy Department, Faculty of Pharmacy, Minia University, Minia, Egypt.

  • Engy A. Wahsh, Asst. Prof. · Clinical Pharmacy Department, Faculty of Pharmacy, October 6 University, Giza, Egypt

  • Fatma M. Mady, Professor · Pharmaceutics department, Faculty of Pharmacy, Minia University, Minia, Egypt.

  • Eman M. Sadek, Lecturer · Clinical pharmacy Department, Faculty of Pharmacy, Minia University, Minia, Egypt.

  • Ahmed Mostafa Abd-Elaziz, Lecturer · Department of Clinical Oncology, Faculty of Medicine, Minia University, Minia, Egypt.

  • Noha Mahmood Abd-Allah, Lecturer · Department of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-23
Primary Completion
2025-01-28
Completion
2025-03-27

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06459193 on ClinicalTrials.gov